Growth Metrics

NovoCure (NVCR) Free Cash Flow (2016 - 2026)

NovoCure's Free Cash Flow history spans 13 years, with the latest figure at -$18.7 million for Q1 2026.

  • On a quarterly basis, Free Cash Flow rose 59.66% to -$18.7 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$48.1 million, a 33.36% increase, with the full-year FY2025 number at -$75.7 million, down 9.32% from a year prior.
  • Free Cash Flow hit -$18.7 million in Q1 2026 for NovoCure, up from -$22.9 million in the prior quarter.
  • Over the last five years, Free Cash Flow for NVCR hit a ceiling of $16.7 million in Q3 2022 and a floor of -$46.3 million in Q1 2025.
  • Historically, Free Cash Flow has averaged -$15.0 million across 5 years, with a median of -$18.7 million in 2026.
  • Biggest five-year swings in Free Cash Flow: tumbled 7898.46% in 2022 and later soared 4959.61% in 2025.
  • Tracing NVCR's Free Cash Flow over 5 years: stood at -$10.1 million in 2022, then crashed by 110.88% to -$21.4 million in 2023, then skyrocketed by 42.03% to -$12.4 million in 2024, then plummeted by 84.78% to -$22.9 million in 2025, then increased by 18.48% to -$18.7 million in 2026.
  • Business Quant data shows Free Cash Flow for NVCR at -$18.7 million in Q1 2026, -$22.9 million in Q4 2025, and $14.9 million in Q3 2025.